YES1
MOLECULAR TARGETYES proto-oncogene 1, Src family tyrosine kinase
YES1 (YES proto-oncogene 1, Src family tyrosine kinase) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting YES1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Dasatinib | 1.39 | 3 |
| 2 | Quercetin | 1.10 | 2 |
| 3 | Axitinib | 1.10 | 2 |
| 4 | Crizotinib | 1.10 | 2 |
| 5 | Sorafenib | 1.10 | 2 |
| 6 | Kaempferols | 0.69 | 1 |
| 7 | Luteolin 5,7,3',4'-tetrahydroxy-flavone, | 0.69 | 1 |
| 8 | Cladribine | 0.69 | 1 |
| 9 | pictilisib | 0.69 | 1 |
| 10 | Pioglitazone | 0.69 | 1 |
| 11 | tyrphostin ag 1478 | 0.69 | 1 |
| 12 | Vemurafenib | 0.69 | 1 |
About YES1 as a Drug Target
YES1 (YES proto-oncogene 1, Src family tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented YES1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
YES1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.